橋本病の世界市場レポート2025年

橋本病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で21億6,000万米ドルに成長します。予測期間の成長は、遠隔医療の利用増加、個別化医療の進歩、早期診断の需要増加、政府の保健イニシアティブの支援、バイオシミラーの採用拡大などに起因すると考えられます。この期間に予想される主な動向には、診断におけるAIの統合、全人的治療アプローチの重視の高まり、家庭用甲状腺検査キットの利用可能性の増加、免疫療法の臨床試験の拡大、自己免疫疾患研究の進展などがあります。

自己免疫疾患の有病率の増加は、今後数年間における橋本病市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って体内の健康な組織を攻撃し、炎症や組織損傷を引き起こすことで発症します。このような自己免疫疾患の増加は、遺伝的素因と正常な免疫機能を乱す環境的誘因の組み合わせによるところが大きいです。免疫系が甲状腺を標的とする橋本病は、自己免疫疾患の根底にあるより広範なメカニズムを例証し、免疫系が誤作動を起こす可能性を強調しています。例えば、2024年11月、ドイツを拠点とする団体Versorgungsatlas.deのデータによると、2022年、7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断されました。この有病率の増加は、橋本病市場の拡大に大きく寄与しています。

ヘルスケア支出の増加は、橋本病市場の成長に大きく寄与すると予想されます。ヘルスケア支出とは、様々な健康状態の予防、診断、治療、リハビリテーションを含むヘルスケアサービスに割り当てられる総財源を指します。この支出の増加は、より良い治療結果、より早い回復、生活の質の向上をもたらす先進医療に対する需要の高まりが主な要因となっています。橋本病は、継続的なモニタリング、ホルモン補充療法、一貫した医学的管理が必要なため、医療費全体に寄与しています。例えば、2024年5月、英国の政府機関であるOffice for National Statisticsは、英国のヘルスケア支出は2022年の0.9％増に対し、2022年から2023年にかけて5.6％増であると報告しています。このような医療費の増加動向は、橋本病市場の成長を促す重要な要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の橋本病：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の橋本病市場：成長率分析
• 世界の橋本病市場の実績：規模と成長, 2019-2024
• 世界の橋本病市場の予測：規模と成長, 2024-2029, 2034F
• 世界の橋本病：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の橋本病市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ストレス関連
• 感染関連
• 自己免疫関連
• 環境関連
• 病気関連
• 混合
• その他のタイプ
• 世界の橋本病市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン補充療法
• 免疫療法
• 抗甲状腺薬
• 手術
• 栄養補助食品
• その他の治療の種類
• 世界の橋本病市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口経路
• 注射経路
• 経皮経路
• その他の投与経路
• 世界の橋本病市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界の橋本病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の橋本病市場、ストレス関連のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性的な心理的ストレス
• 仕事関連のストレス
• 心的外傷後ストレス
• ライフスタイルに起因するストレス
• 不安とうつ病によるストレス
• 世界の橋本病市場、感染関連のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ウイルス感染
• 細菌感染症
• 真菌感染症
• 寄生虫感染症
• 慢性炎症性感染症
• 世界の橋本病市場自己免疫関連疾患のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 併存する自己免疫性甲状腺炎
• 1型糖尿病
• 関節リウマチ
• 全身性エリテマトーデス（SLE）
• セリアック病
• 世界の橋本病市場環境関連、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線被曝
• ヨウ素の不均衡
• 化学物質への曝露
• 重金属毒性
• 内分泌かく乱物質
• 世界の橋本病市場、疾患関連のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多嚢胞性卵巣症候群（PCOS）
• 心血管疾患
• 慢性疲労症候群
• 線維筋痛症
• メタボリックシンドローム
• 世界の橋本病市場環境関連、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 放射線被曝
• ヨウ素の不均衡
• 化学物質への曝露
• 重金属毒性
• 内分泌かく乱物質
• 世界の橋本病市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤性甲状腺炎
• 産後甲状腺炎
• 無痛性甲状腺炎
• 遺伝的素因
• 特発性の場合

第7章 地域別・国別分析

• 世界の橋本病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の橋本病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 橋本病市場：競合情勢
• 橋本病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Lupin Limited
• Lannett Company Inc.
• Aurore Life Sciences Inc.
• Acella Pharmaceuticals LLC
• Sigmapharm Laboratories LLC
• Jerome Stevens Pharmaceuticals Inc.
• RLC Labs Inc.
• AdvaCare Pharma
• GNH India Ltd.
• Clayman Thyroid Center P.C.
• Rakshit Pharmaceuticals Ltd.
• Lexicare Pharma Private Limited
• Forest Pharmaceuticals Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 橋本病市場2029：新たな機会を提供する国
• 橋本病市場2029：新たな機会を提供するセグメント
• 橋本病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hashimoto's disease, also known as Hashimoto's thyroiditis or chronic lymphocytic thyroiditis, is an autoimmune condition in which the immune system mistakenly targets the thyroid gland-a small, butterfly-shaped gland located at the base of the neck. This immune attack causes persistent inflammation, which can impair the gland's ability to produce thyroid hormones, frequently leading to hypothyroidism. Hypothyroidism is marked by symptoms such as a slowed metabolism, fatigue, weight gain, cold sensitivity, and depression.

The primary types of Hashimoto's disease include stress-related, infection-related, autoimmune-related, environmental-related, disease-related, mixed, and other types. Stress-related Hashimoto's involves symptoms or flare-ups triggered or intensified by physical or emotional stress, which can influence immune function and worsen autoimmune responses. Treatment options include hormone replacement therapy, immunotherapy, antithyroid medications, surgery, dietary supplements, and other approaches. Medications are delivered through various routes, including oral, injectable, transdermal, and others. These treatments are distributed via hospital pharmacies, retail pharmacies, online pharmacies, and additional channels, and are utilized by a range of end users such as hospitals, specialty clinics, homecare environments, and others.

The hashimotos disease market research report is one of a series of new reports from The Business Research Company that provides hashimotos disease market statistics, including hashimotos disease industry global market size, regional shares, competitors with the hashimotos disease market share, hashimotos disease market segments, market trends, and opportunities, and any further data you may need to thrive in the hashimotos disease industry. This hashimotos disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hashimotos disease market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to increasing awareness of thyroid disorders, advancements in diagnostic techniques, a rise in the prevalence of autoimmune diseases, growing healthcare expenditure, and the expansion of endocrinology clinics.

The hashimotos disease market size is expected to see strong growth in the next few years. It will grow to $2.16 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to the increasing use of telemedicine, advancements in personalized medicine, rising demand for early diagnosis, supportive government health initiatives, and growing adoption of biosimilars. Key trends expected during this period include the integration of AI in diagnostics, a growing emphasis on holistic treatment approaches, increased availability of at-home thyroid testing kits, expansion of clinical trials for immunotherapies, and progress in autoimmune disease research.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the Hashimoto's disease market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own healthy tissues, leading to inflammation and tissue damage. This rise in autoimmune conditions is largely attributed to a combination of genetic predisposition and environmental triggers that disrupt normal immune function. Hashimoto's disease, in which the immune system targets the thyroid gland, exemplifies the broader mechanisms underlying autoimmune diseases and underscores the immune system's potential to malfunction. For example, in November 2024, data from Versorgungsatlas.de, a Germany-based organization, revealed that in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disorder-resulting in a raw prevalence rate of 8.61%. This growing prevalence is a significant factor contributing to the expansion of the Hashimoto's disease market.

The rising healthcare expenditure is expected to contribute significantly to the growth of the Hashimoto's disease market. Healthcare expenditure refers to the total financial resources allocated to healthcare services, including prevention, diagnosis, treatment, and rehabilitation of various health conditions. This increase in spending is largely driven by the growing demand for advanced medical treatments that provide better outcomes, faster recovery, and improved quality of life. Hashimoto's disease contributes to overall healthcare costs due to its need for ongoing monitoring, hormone replacement therapy, and consistent medical management-factors that escalate resource utilization and expenses over time. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a 0.9% increase in 2022. This trend in rising healthcare expenditure is a key factor fueling the growth of the Hashimoto's disease market.

In October 2024, Acella Pharmaceuticals LLC, a U.S.-based specialty pharmaceutical company, partnered with Paloma Health to enhance virtual access to personalized care for individuals with hypothyroidism. Through this collaboration, the two organizations aim to improve comprehensive care for patients with hypothyroidism and Hashimoto's disease by connecting them with licensed telehealth providers who can deliver customized treatment options, including NP Thyroid. Paloma Health is a U.S.-based virtual platform specializing in telehealth services for hypothyroidism and Hashimoto's disease, offering medical consultations, diagnostic testing, and lifestyle management to support personalized care.

Major players in the hashimotos disease market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Abbott Laboratories, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Lupin Limited, Lannett Company Inc., Aurore Life Sciences Inc., Acella Pharmaceuticals LLC, Sigmapharm Laboratories LLC, Jerome Stevens Pharmaceuticals Inc., RLC Labs Inc., AdvaCare Pharma, GNH India Ltd., Clayman Thyroid Center P.C., Rakshit Pharmaceuticals Ltd., Lexicare Pharma Private Limited, Forest Pharmaceuticals Inc.

North America was the largest region in the hashimotos disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hashimotos disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hashimotos disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hashimotos disease market consists of revenues earned by entities by providing services such as diagnosis and screening, pharmaceutical therapy management, nutritional and lifestyle counseling, autoimmune disease monitoring, patient education and support programs, and telemedicine and digital health monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The hashimotos disease market also includes sales of levothyroxine sodium tablets, liothyronine (T3) tablets, desiccated thyroid extract, vitamin and nutritional supplements, and anti-inflammatory and immunomodulatory products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hashimotos Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hashimotos disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hashimotos disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hashimotos disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Stress Related; Infection Related; Autoimmune Related; Environmental Related; Disease Related; Mixed; Other Types
• 2) By Treatment Type: Hormone Replacement Therapy; Immunotherapy; Antithyroid Medication; Surgery; Dietary Supplements; Other Treatment Types
• 3) By Route Of Administration: Oral Route; Injectable Route; Transdermal Route; Other Route Of Administrations
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End USer: Hospitals; Speciality Clinics; Homecare; Other End Users
• Subsegments:
• 1) By Stress Related: Chronic Psychological Stress; Work-Related Stress; Post-Traumatic Stress; Lifestyle-Induced Stress; Anxiety And Depression-Induced Stress
• 2) By Infection Related: Viral Infections; Bacterial Infections; Fungal Infections; Parasitic Infections; Chronic Inflammatory Infections
• 3) By Autoimmune Related: Coexisting Autoimmune Thyroiditis; Type 1 Diabetes; Rheumatoid Arthritis; Systemic Lupus Erythematosus (SLE); Celiac Disease
• 4) By Environmental Related: Exposure To Radiation; Iodine Imbalance; Chemical Exposure; Heavy Metal Toxicity; Endocrine Disruptors
• 5) By Disease Related: Polycystic Ovary Syndrome (PCOS); Cardiovascular Disorders; Chronic Fatigue Syndrome; Fibromyalgia; Metabolic Syndrome
• 6) By Mixed: Stress And Autoimmune Combined; Infection And Environmental Combined; Autoimmune And Disease Combined; Stress And Environmental Combined; Multiple Etiology Overlap
• 7) By Other Types: Drug-induced Thyroiditis; Postpartum Thyroiditis; Silent Thyroiditis; Genetic Predisposition; Idiopathic Cases
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Abbott Laboratories; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hashimotos Disease Market Characteristics

3. Hashimotos Disease Market Trends And Strategies

4. Hashimotos Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hashimotos Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hashimotos Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hashimotos Disease Market Growth Rate Analysis
• 5.4. Global Hashimotos Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hashimotos Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hashimotos Disease Total Addressable Market (TAM)

6. Hashimotos Disease Market Segmentation

• 6.1. Global Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stress Related
• Infection Related
• Autoimmune Related
• Environmental Related
• Disease Related
• Mixed
• Other Types
• 6.2. Global Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Replacement Therapy
• Immunotherapy
• Antithyroid Medication
• Surgery
• Dietary Supplements
• Other Treatment Types
• 6.3. Global Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Route
• Injectable Route
• Transdermal Route
• Other Route Of Administrations
• 6.4. Global Hashimotos Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Hashimotos Disease Market, Segmentation By End USer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Speciality Clinics
• Homecare
• Other End Users
• 6.6. Global Hashimotos Disease Market, Sub-Segmentation Of Stress Related, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Psychological Stress
• Work-Related Stress
• Post-Traumatic Stress
• Lifestyle-Induced Stress
• Anxiety And Depression-Induced Stress
• 6.7. Global Hashimotos Disease Market, Sub-Segmentation Of Infection Related, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Infections
• Bacterial Infections
• Fungal Infections
• Parasitic Infections
• Chronic Inflammatory Infections
• 6.8. Global Hashimotos Disease Market, Sub-Segmentation Of Autoimmune Related, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Coexisting Autoimmune Thyroiditis
• Type 1 Diabetes
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus (SLE)
• Celiac Disease
• 6.9. Global Hashimotos Disease Market, Sub-Segmentation Of Environmental Related, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exposure To Radiation
• Iodine Imbalance
• Chemical Exposure
• Heavy Metal Toxicity
• Endocrine Disruptors
• 6.10. Global Hashimotos Disease Market, Sub-Segmentation Of Disease Related, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Polycystic Ovary Syndrome (PCOS)
• Cardiovascular Disorders
• Chronic Fatigue Syndrome
• Fibromyalgia
• Metabolic Syndrome
• 6.11. Global Hashimotos Disease Market, Sub-Segmentation Of Environmental Related, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exposure To Radiation
• Iodine Imbalance
• Chemical Exposure
• Heavy Metal Toxicity
• Endocrine Disruptors
• 6.12. Global Hashimotos Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug-induced Thyroiditis
• Postpartum Thyroiditis
• Silent Thyroiditis
• Genetic Predisposition
• Idiopathic Cases

7. Hashimotos Disease Market Regional And Country Analysis

• 7.1. Global Hashimotos Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hashimotos Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hashimotos Disease Market

• 8.1. Asia-Pacific Hashimotos Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hashimotos Disease Market

• 9.1. China Hashimotos Disease Market Overview
• 9.2. China Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hashimotos Disease Market

• 10.1. India Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hashimotos Disease Market

• 11.1. Japan Hashimotos Disease Market Overview
• 11.2. Japan Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hashimotos Disease Market

• 12.1. Australia Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hashimotos Disease Market

• 13.1. Indonesia Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hashimotos Disease Market

• 14.1. South Korea Hashimotos Disease Market Overview
• 14.2. South Korea Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hashimotos Disease Market

• 15.1. Western Europe Hashimotos Disease Market Overview
• 15.2. Western Europe Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hashimotos Disease Market

• 16.1. UK Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hashimotos Disease Market

• 17.1. Germany Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hashimotos Disease Market

• 18.1. France Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hashimotos Disease Market

• 19.1. Italy Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hashimotos Disease Market

• 20.1. Spain Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hashimotos Disease Market

• 21.1. Eastern Europe Hashimotos Disease Market Overview
• 21.2. Eastern Europe Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hashimotos Disease Market

• 22.1. Russia Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hashimotos Disease Market

• 23.1. North America Hashimotos Disease Market Overview
• 23.2. North America Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hashimotos Disease Market

• 24.1. USA Hashimotos Disease Market Overview
• 24.2. USA Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hashimotos Disease Market

• 25.1. Canada Hashimotos Disease Market Overview
• 25.2. Canada Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hashimotos Disease Market

• 26.1. South America Hashimotos Disease Market Overview
• 26.2. South America Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hashimotos Disease Market

• 27.1. Brazil Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hashimotos Disease Market

• 28.1. Middle East Hashimotos Disease Market Overview
• 28.2. Middle East Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hashimotos Disease Market

• 29.1. Africa Hashimotos Disease Market Overview
• 29.2. Africa Hashimotos Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hashimotos Disease Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hashimotos Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hashimotos Disease Market Competitive Landscape And Company Profiles

• 30.1. Hashimotos Disease Market Competitive Landscape
• 30.2. Hashimotos Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Hashimotos Disease Market Other Major And Innovative Companies

• 31.1. Viatris Inc.
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Lupin Limited
• 31.4. Lannett Company Inc.
• 31.5. Aurore Life Sciences Inc.
• 31.6. Acella Pharmaceuticals LLC
• 31.7. Sigmapharm Laboratories LLC
• 31.8. Jerome Stevens Pharmaceuticals Inc.
• 31.9. RLC Labs Inc.
• 31.10. AdvaCare Pharma
• 31.11. GNH India Ltd.
• 31.12. Clayman Thyroid Center P.C.
• 31.13. Rakshit Pharmaceuticals Ltd.
• 31.14. Lexicare Pharma Private Limited
• 31.15. Forest Pharmaceuticals Inc.

32. Global Hashimotos Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hashimotos Disease Market

34. Recent Developments In The Hashimotos Disease Market

35. Hashimotos Disease Market High Potential Countries, Segments and Strategies

• 35.1 Hashimotos Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hashimotos Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hashimotos Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer